CA3258734A1 - COMPOSITIONS CONTAINING 5,10-METHYLENE-(6R)-DISODIC TETRAHYDROFOLATE - Google Patents

COMPOSITIONS CONTAINING 5,10-METHYLENE-(6R)-DISODIC TETRAHYDROFOLATE

Info

Publication number
CA3258734A1
CA3258734A1 CA3258734A CA3258734A CA3258734A1 CA 3258734 A1 CA3258734 A1 CA 3258734A1 CA 3258734 A CA3258734 A CA 3258734A CA 3258734 A CA3258734 A CA 3258734A CA 3258734 A1 CA3258734 A1 CA 3258734A1
Authority
CA
Canada
Prior art keywords
methylene
tetrahydrofolic acid
pct
citrate
lyophilized composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3258734A
Other languages
English (en)
French (fr)
Inventor
Rudolf Moser
Viola Groehn
Thomas Ammann
Jean-Pierre Knapp
Marianne Svaerd
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA3258734A1 publication Critical patent/CA3258734A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3258734A 2022-06-08 2023-06-05 COMPOSITIONS CONTAINING 5,10-METHYLENE-(6R)-DISODIC TETRAHYDROFOLATE Pending CA3258734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22177932.5 2022-06-08
EP22177932 2022-06-08
PCT/EP2023/064972 WO2023237484A1 (en) 2022-06-08 2023-06-05 Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate

Publications (1)

Publication Number Publication Date
CA3258734A1 true CA3258734A1 (en) 2023-12-14

Family

ID=81984853

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3258734A Pending CA3258734A1 (en) 2022-06-08 2023-06-05 COMPOSITIONS CONTAINING 5,10-METHYLENE-(6R)-DISODIC TETRAHYDROFOLATE

Country Status (9)

Country Link
US (1) US20250360135A1 (enExample)
EP (1) EP4536187A1 (enExample)
JP (1) JP2025518274A (enExample)
KR (1) KR20250022145A (enExample)
CN (1) CN119365186A (enExample)
AU (1) AU2023282347A1 (enExample)
CA (1) CA3258734A1 (enExample)
IL (1) IL317395A (enExample)
WO (1) WO2023237484A1 (enExample)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483475D1 (de) 1983-05-20 1990-11-29 Bengt Gustavsson Anordnung zur uebertragung einer substanz.
CH682664A5 (en) * 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
US5997915A (en) * 1996-01-31 1999-12-07 South Alabama Medical Science Foundation Compositions for human and animal consumption containing reduced folates and methods for making and using same
CH697021A5 (de) 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
KR20080074201A (ko) 2005-12-02 2008-08-12 어드벤트륵스 파마슈티칼스, 인크. 5,10 메틸렌테트라히드로폴레이트의 안정한 약학 조성물
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
US10059710B2 (en) 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid
DK3668516T3 (da) 2017-08-16 2021-12-13 Merck Patent Gmbh Stabile lyofilisater omfattende 5,10-methylen-(6r)-tetrahydrofolsyre og en dicarboxylsyre
CN107892692A (zh) * 2017-12-28 2018-04-10 华东理工大学 (6s)‑5‑甲基四氢叶酸锌盐的制备方法及其应用

Also Published As

Publication number Publication date
EP4536187A1 (en) 2025-04-16
IL317395A (en) 2025-02-01
KR20250022145A (ko) 2025-02-14
CN119365186A (zh) 2025-01-24
AU2023282347A1 (en) 2025-01-16
JP2025518274A (ja) 2025-06-12
US20250360135A1 (en) 2025-11-27
WO2023237484A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
EP2991619B1 (en) Stable pharmaceutical composition containing folates
US20160030573A1 (en) Stable pharmaceutical compositions of 5,10-methylenetetrahydrofolate
US20090325978A1 (en) Stable lyophilized preparation
BG65827B1 (bg) Фармацевтични разтвори от левосимендан
US9301922B1 (en) Stable high strength pharmaceutical composition of levoleucovorin
US20090221594A1 (en) Stable pharmaceutical compositions of 5, 10 methylenetrahydrofolate
US20250360135A1 (en) Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate
US20250319022A1 (en) Concentrated solutions comprising sodium 5,10-methylene-(6r)-tetrahydrofolate
US20060063833A1 (en) Ready-to-use oxaliplatin solutions
US20070276008A1 (en) Pharmaceutical formulation comprising glycine as a stabilizer
US20250319089A1 (en) Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid
US20220151923A1 (en) Stable liquid compositions of pemetrexed
EP1039905B1 (en) Pharmaceutical formulation comprising glycine as a stabilizer
US20260000671A1 (en) Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid
WO2023237483A1 (en) Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid
CA3258607A1 (en) STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID AND NACL
WO2025165852A1 (en) Liquid formulations of lurbinectedin